Technology and Products
BioDiem is an Australian-based biotechnology company with a focus on developing and commercialising vaccine and infectious disease therapies.
The strength of our global partnering network is a key advantage of the Company. Our partners (the World Health Organisation and the US National Institutes of Health among others) are world-leading institutions that have in some cases facilitated our access to major markets (e.g. China and India).
Our strategy is to grow a diverse infectious disease treatment and prevention portfolio.
We currently earn revenue through licensing of LAIV influenza vaccine technology to Indian and Chinese partners.
In parallel to our LAIV technology commercialisation, our subsidiary, Opal Biosciences Ltd, is developing BDM-I, our novel antimicrobial compound which has shown impressive activity in screening studies against a range of pathogenic microbes. Opal-T, in development for the treatment of infections of the skin, has shown activity in vitro against methicillin-resistant Staph aureus (MRSA) and Neisseria gonorrhoea. The continued rise in antibiotic-resistant strains of bacteria such as the deadly MRSA, and the increasing problem of clinical fungal infections, have led to significant interest in compounds which may address the lack of treatment options. Patents for BDM-I have been granted worldwide.
For further information on any of our technologies, please contact info@biodiem.com.
